Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with Type 2 diabetes not using insulin.
Dexcom's continuous glucose monitoring system in Maryland, July 15, 2021. A new study says use of its G7 monitor led to improved blood sugar control in patients with Type 2 diabetes not using insulin.
The 26-week study showed a 1.6% reduction in blood sugar with the use of the G7 monitor. NEW ORLEANS — Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, compared with routine care, according to study results.
The 26-week study tested 283 non-insulin-using diabetic patients, half of whom were assigned to Dexcom's G7 and half used self-monitoring of blood glucose. Most participants were on common diabetes medication such as metformin, GLP-1s and SGLT2s. Participants using the Dexcom G7 saw an average 1.6% reduction in their blood sugar levels at 26 weeks, a 0.9% greater reduction than those who used self-monitoring.
"Our hope is that this will substantially influence and it'll improve access for all people with type 2, including those not on insulin to CGMs," Tamara Oser, professor at the University of Colorado Anschutz and the study's principal investigator, told Reuters. Continuous glucose monitors are wearable devices that track blood sugar without finger pricks. Rising awareness, broader insurance coverage and ease of use are boosting adoption of devices like Dexcom's G7.
The study found that using Dexcom G7 further lowered blood sugar levels when combined with common diabetes medications. Among participants using GLP-1 drugs, those using the Dexcom G7 saw a 1.4% drop in blood sugar levels, compared with a 0.2% reduction in the control group.
"... it proves without a doubt that there's significant benefit here for these users. I think both the clinical community as well as the health care system and payers, they will, with this type of result, recognize both the health benefits, as well as the economic benefit," Dexcom CEO Jake Leach told Reuters. These results "will help establish a new standard of care in the U.S. and around the world," he said in a statement.
A six-month extension phase of the study is currently being conducted, which will provide data for up to 12 months. The Key Takeaways for this article were generated with the assistance of large language models and reviewed by our editorial team. The article, itself, is solely human-written. Utah girl named national Children's Miracle Network champion after lifetime of health challenges
Please follow us on Google to support us Traffic Weather Sports Classifieds Cars Jobs Homes Television Radio Salt Lake Utah Local Health Science Business Technology
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
‘Scarier’ Type of Lyme Disease Spreading in the US Causes More Severe Symptoms: Doctors ExplainThe illness is still considered to be Lyme disease, but it comes with “very, very high level of bacteria” in the blood and more severe symptoms. Doctors explain the differences.
Read more »
Popular Blood Pressure Meds Linked to Kidney Damage Risk in Type 2 DiabetesA common class of blood pressure medications might contribute to kidney damage among people with type 2 diabetes, a new study says.
Read more »
Picking the right type of menstrual products cuts symptoms for 78% of womenAunt Flo might have met her match.
Read more »
James Gandolfini's Against-Type Role in 'Enough Said'Explore James Gandolfini's surprising and nuanced performance as Albert in Nicole Holofcener's Enough Said, a role that diverged sharply from his iconic Tony Soprano character and showcased his remarkable range as an actor.
Read more »